• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by DURECT Corporation

    2/16/24 4:09:22 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email
    SC 13G 1 tm246550d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    Durect Corp.
    (Name of Issuer)
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    266605500
    (CUSIP Number)
     
    February 14, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 266605500   Page 2 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

     

    R. Scott Asen

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    Not Applicable

    (a) ¨
    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF SHARES
    BENEFICIALLY OWNED BY EACH
    REPORTING PERSON WITH
    5

    SOLE VOTING POWER

     

    1,080,000*

    6

    SHARED VOTING POWER

     

    450,000**

    7

    SOLE DISPOSITIVE POWER

     

    1,080,000*

    8

    SHARED DISPOSITIVE POWER

     

    450,000**

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,530,000 shares

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    Not applicable

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.13%

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

      

    * Includes 30,000 shares held by a certain charitable foundation of which the Reporting Person is a trustee. The other trustee has designated investment authority for the foundation to the Reporting Person. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest (see Item 4).

     

    ** Consists of shares held by certain Managed Accounts, as to which the Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest (see Item 4).

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 266605500   Page 3 of 6 Pages

     

    Item 1(a).Name of Issuer:

     

    Durect Corp.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    10240 Bubb Road

    Cupertino, CA 95014-1417

     

    Item 2(a).Name of Person Filing:

     

    R. Scott Asen (the “Reporting Person”)

     

    Item 2(b).Address of Principal Business Offices or, if none, Residence:

     

    Asen and Co.

    222 ½ East 49th Street

    New York, New York 10017

     

    Item 2(c).Citizenship:

     

    The Reporting Person is a citizen of the United States of America.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share

     

    Item 2(e).CUSIP Number:

     

    266605500

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 266605500   Page 4 of 6 Pages

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

     

    The Reporting Person directly owns 1,050,000 shares. The Reporting Person is a trustee of The Asen Foundation (the “Foundation”), a not-for-profit foundation which owns 30,000 shares, and has been delegated investment authority for the Foundation by the other trustee of the Foundation. The Reporting Person is the President of Asen and Co., which provides certain advisory services to accounts (the “Managed Accounts”) that own 450,000 shares. The Reporting Person may be deemed to beneficially own the shares held by the Foundation and by the Managed Accounts, but the Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest.

     

    (b)Percent of class:

     

    5.13%, consisting of: (1) 1,050,000 shares owned directly by the Reporting Person, which represent approximately 3.52% of the issued and outstanding shares of Common Stock of the Issuer, (2) 30,000 shares owned by the Foundation, which represent approximately 0.10% of the issued and outstanding shares of Common Stock of the issuer and (3) 450,000 shares owned by the Managed Accounts, which represent approximately 1.51% of the issued and outstanding shares of Common Stock of the issuer.

     

    The foregoing percentages are calculated based on 29,828,891 shares of Common Stock outstanding as of November 13, 2023, as reported in the issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023.

     

      (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote:

     

    The Reporting Person has sole voting power over 1,050,000 shares which he owns directly. The Reporting Person has sole voting power over 30,000 shares which are owned by the Foundation and as to which the Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.

     

    (ii)Shared power to vote or direct the vote:

     

    The Reporting Person has shared voting power over 450,000 shares owned by the Managed Accounts. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    The Reporting Person has sole voting power over 1,050,000 shares which he owns directly. The Reporting Person has sole voting power over 30,000 shares which are owned by the Foundation and as to which the Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 266605500   Page 5 of 6 Pages

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    The Reporting Person has shared voting power over 450,000 shares owned by the Managed Accounts. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    See response to Item 4.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 266605500   Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 16, 2024
       
      By: /s/ R. Scott Asen
        R. Scott Asen

     

     

     

    Get the next $DRRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Durect with a new price target

      HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

      5/5/21 6:31:29 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital reiterated coverage on Durect with a new price target

      Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      2/3/21 8:15:53 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

      CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (www.durect.com) is a late-stage biopharmaceutical company pion

      2/4/25 7:30:00 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for POSIMIR

      Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

      2/2/21 7:24:30 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Financials

    Live finance-specific insights

    See more
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

      -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

      11/13/24 4:01:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    SEC Filings

    See more
    • SEC Form 10-K filed by DURECT Corporation

      10-K - DURECT CORP (0001082038) (Filer)

      3/27/25 5:26:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DURECT CORP (0001082038) (Filer)

      3/26/25 4:16:15 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by DURECT Corporation

      SCHEDULE 13G/A - DURECT CORP (0001082038) (Subject)

      2/21/25 5:37:08 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

      CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

      3/21/23 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

      CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

      7/5/22 8:30:00 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DURECT Corporation

      SC 13G/A - DURECT CORP (0001082038) (Subject)

      11/19/24 5:10:25 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      3/27/24 3:15:14 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      2/16/24 4:09:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Sussman Norman

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:47:15 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Papp Timothy M.

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:46:24 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President & CEO Brown James E

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:42:29 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care